Autologous Dendritic Cells Loaded with Allogenic Tumor Lysate for Surgically Resected Pancreatic Cancer Patients (REACtiVe Trial)

Published: 14-09-2017 Last updated: 12-04-2024

To investigate feasibility, safety and toxicity as well as immune-response of an allogeneic tumor cell lysate (PheraLys) loaded onto autologous dendritic cells (MesoPher) in resected pancreatic cancer patients who received adjuvant standard of care...

Ethical review	Not approved
Status	Will not start
Health condition type	Exocrine pancreas conditions
Study type	Interventional

Summary

ID

NL-OMON44379

Source ToetsingOnline

Brief title REACtiVe Trial

Condition

- Exocrine pancreas conditions
- Gastrointestinal neoplasms malignant and unspecified

Synonym

pancreatic cancer, pancreatic ductal adenocarcinoma

Research involving

Human

Sponsors and support

Primary sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam **Source(s) of monetary or material Support:** Ministerie van OC&W,Amphera b.v.,Amphera en TKI-LSH ondersteuning

Intervention

Keyword: Dendritic cell, Immunotherapy, Pancreatic cancer

Outcome measures

Primary outcome

The primary endpoint of this project proposal is to determine the feasibility

of administering MesoPher after standard of care adjuvant therapy in patients

with resected pancreatic cancer. We deem this treatment feasible in case 6 out

of 10 patients are able to complete the proposed treatment.

Secondary outcome

As a secondary endpoint we will assess the safety of MesoPher in surgically resected pancreatic cancer patients.

In addition, we will determine the systemic immune profile, with emphasis on T lymphocytes, in surgically resected pancreatic cancer patients; and investigate how these immune profiles are affected by MesoPher treatment for individual patients.

Study description

Background summary

The annual incidence of patients developing pancreatic cancer in the Netherlands is approximately 3500. In 2030, pancreatic cancer is expected to be

2 - Autologous Dendritic Cells Loaded with Allogenic Tumor Lysate for Surgically Res ... 13-05-2025

the second leading cause of cancer-related death. The 1-year overall survival (OS) for pancreatic cancer in the Netherlands is 20%; 5-year OS is only 3%.

Current treatments for pancreatic cancer include cytoreductive surgery, radioand chemotherapy. To date, surgical resection is the mainstay of potentially curative treatment for patients with (borderline) resectable disease. However, ten years after resection, OS is 4%, demonstrating that cure is exceedingly rare. Apparently, the vast majority of patients with (borderline) resectable pancreatic cancer on imaging have occult metastatic disease. In the Netherlands, almost a third of these patients is found to have more advanced disease (locally advanced or metastatic) during surgical exploration and consequently does not undergo a resection. In the end, only 5-25% of all pancreatic cancer patients are eligible to undergo surgical resection.

We are in need of new treatments in order to curb the progression of pancreatic cancer. In contrast to radiotherapy and chemotherapy, dendritic cell vaccination may elicit specific anti-cancer responses without damaging surrounding healthy tissue and therefore would be a suitable complementary treatment to the current treatment regime.

While no clinical data is available concerning the efficacy and safety of allogenic tumor lysate pulsed DC vaccination in patients with pancreatic cancer, DC therapy with either autologous or allogenic tumor lysate has shown its feasibility and safety in patients suffering from MM. Here we propose to use PheraLys, a tumor lysate derived from five different malignant MM cell lines to load autologous DCs (MesoPher) for patient treatment. Microarray analysis of these five MM cell lines revealed that PheraLys contains a broad spectrum (>120) of tumor associated antigens (TAA) and cancer germline antigens (CGA) which are expected to induce high-avidity T cell responses within the patients. We argue that MesoPher possesses the potential to induce strong anti-tumor responses in patients suffering from pancreatic cancer as well, given the broad overlap of TAA and CGA expression between the two tumor types.

Compared to other cancer types, pancreatic cancer tissue specimens contain a relatively low number of cancer cells, making autologous tumor lysate for DC vaccination ineffective. We propose that the use of a lysate derived from five different MM cell lines to pulse DCs in pancreatic cancer patients has a higher feasibility than using autologous tumor lysate. Both MM and pancreatic cancer share multiple, clinically proven TAAs such as but not limited to: WT-1, mesothelin and MUC-1. In addition, unlike ACT with TCR transduced T cells which requires patients to have an HLA matching the therapeutic, whole tumor lysate therapy in the context of DC vaccination is applicable to all patients regardless of their HLA type.

Therefore, in this study we will primarily investigate whether it is feasible to use an allogeneic source of tumor antigens from MM cell lines in pancreatic cancer patients. Our secondary objective is to assess the safety and toxicity of the treatment as well as the occurrence of anti-tumor/immune responses within individual pancreatic cancer patients.

Study objective

To investigate feasibility, safety and toxicity as well as immune-response of an allogeneic tumor cell lysate (PheraLys) loaded onto autologous dendritic cells (MesoPher) in resected pancreatic cancer patients who received adjuvant standard of care treatment.

Study design

Single center prospective open label phase I study.

Intervention

Leukapheresis is performed of which the monocytes are used for differentiation to dendritic cells using specific cytokines. Pulsed autologous dendritic cells (MesoPher) are re-injected three times every two weeks. After the third injection with MesoPher, revaccinations to boost the immune system are given after 3 and 6 months.

Furthermore 3 CT scans will be performed to assess treatment response and bloodsamples will be collected to monitor the immune system before, during and after treatment.

Study burden and risks

Patients have to undergo extra outpatient clinic visits for this study and extra invasive procedures specifically for this trial, i.e. intravenous catheter placement. Although these are invasive procedures, associated risks are limited. Intravenous access is necessary during every visit, i.e. for leukapheresis, for drawing blood samples and for injection of the dendritic cells. Leukapheresis is a standard procedure and will be performed according to our internal guidelines. There is a limited risk for transient thrombocytopenia and leukopenia after performance of the leukapheresis. Adverse events due to administration of autologous cells that have been loaded with allogeneic human materials pose a theoretical risk. However, since patients are not treated with the allogenic lysate itself, but with autologous dendritic cells that have been processed and therefore only present the lysate-derived antigens, we expect the associated risks to be limited. Previous clinical studies have shown that injection with tumor lysate-pulsed autologous dendritic cells was well tolerated without major systemic toxicity, with the exception of low-grade flu-like symptoms like fever and rigors.

Contacts

Public Erasmus MC, Universitair Medisch Centrum Rotterdam

's-Gravendijkwal 230 Rotterdam 3015 CE NL **Scientific** Erasmus MC, Universitair Medisch Centrum Rotterdam

's-Gravendijkwal 230 Rotterdam 3015 CE NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

* Surgically resected pancreatic cancer.

* Completed post-operative standard treatment. Patients who did not complete standard of care due to toxicity or who are not able to start standard of care due to specific reasons are allowed to participate in the study after approval of the coordinating investigator.

* No disease activity as assessed by radiological imaging.

* Patients must be at least 18 years old and must be able to give written informed consent. * Patients must be ambulatory (WHO-ECOG performance status 0,1 or 2) and in stable medical condition.

* Patients must have normal organ function and adequate bone marrow reserve: absolute neutrophil count > $1.0 \times 10E9/I$, platelet count > $100 \times 10E9/I$, and Hb > 6.0 mmol/I (as determined during screening).

* Positive DTH skin test (induration > 2mm after 48 hrs) against at least one positive control

5 - Autologous Dendritic Cells Loaded with Allogenic Tumor Lysate for Surgically Res ... 13-05-2025

antigen tetanus toxoid (see section 8.3 for DTH skin test procedure).

- * Ability to return to the hospital for adequate follow-up as required by this protocol.
- * Written informed consent according to ICH-GCP.

Exclusion criteria

- * Medical or psychological impediment to probable compliance with the protocol.
- * Current or previous treatment with immunotherapeutic agents.

* Current use of steroids (or other immunosuppressive agents). Patients must have had 6 weeks of discontinuation and must stop any such treatment during the time of the study. Prophylactic usage of dexamethasone during chemotherapy is excluded from this 6 weeks interval.

* Prior malignancy except adequately treated basal cell or squamous cell skin cancer, superficial or in-situ cancer of the bladder or other cancer for which the patient has been disease-free for five years.

* Serious concomitant disease, or active infections.

* History of autoimmune disease or organ allografts (or with active acute or chronic infection, including HIV and viral hepatitis).

* Serious intercurrent chronic or acute illness such as pulmonary disease (asthma or COPD), cardiac disease (NYHA class III or IV), hepatic disease or other illness considered by the study coordinator to constitute an unwarranted high risk for investigational DC treatment.

- * Known allergy to shell fish (may contain keyhole limpet hemocyanin (KLH).
- * Pregnant or lactating women.

* Inadequate peripheral vein access to perform leukapheresis.

- * Concomitant participation in another clinical trial (except participation in a biobank study).
- * An organic brain syndrome or other significant psychiatric abnormality which would compromise the ability to give informed consent, and preclude participation in the full protocol and follow-up.

* Absence of assurance of compliance with the protocol. Lack of availability for follow-up assessment.

Study design

Design

Study phase:2Study type:InterventionalMasking:Open (masking not used)Control:UncontrolledPrimary purpose:Treatment

Recruitment

NL	
Recruitment status:	Will not start
Enrollment:	10
Туре:	Anticipated

Medical products/devices used

Product type:	Medicine
Generic name:	Somatic cells autologous

Ethics review

Approved WMO	
Date:	14-09-2017
Application type:	First submission
Review commission:	CCMO: Centrale Commissie Mensgebonden Onderzoek (Den Haag)
Not approved	
Date:	05-10-2017
Application type:	First submission
Review commission:	CCMO: Centrale Commissie Mensgebonden Onderzoek (Den Haag)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register EudraCT CCMO ID EUCTR2017-003485-26-NL NL63102.000.17